• Revenue down 8.3% to $764,453
• Loss from operations up 519.9% to $3,586,294
• Cash and cash equivalents at $4,951,502

DorsaVi Limited and its controlled entities reported a loss of $3,586,294 for the half-year ended 31 December 2025, up 519.9% from the previous corresponding period. Total revenue for the six months decreased by 8.3% to $764,453, with sales revenue down 8.0% to $523,780. The loss was attributed to a $2,938,167 increase in operating expenditure, primarily due to higher share-based payments. Cash and cash equivalents as at 31 December 2025 were $4,951,502, up from $2,293,549 at 30 June 2025. The company highlighted several key business risks, including the need to enhance its intellectual property, potential competition, reliance on reimbursement in the medical sector, and general economic conditions. DorsaVi is not currently profitable, and there is no guarantee that its sales and product rollout will result in profitability. The company undertook several capital raisings during the period to fund its operations and expansion.